![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
LA Merkel, LM Rivera, DJ Colussi, MH Perrone, GJ Smits and BF Cox
Rhone-Poulenc Rorer Central Research, Collegeville, Pennsylvania.
In this report, we demonstrate that the adenosine agonist N-5'-ethyl-N6- (cyclopentyl) adenosine-5'-uronamide (RG14202) is a vasorelaxant in porcine coronary arterial rings (EC50 = 0.37 +/- 0.054 microM; n = 19). This vasorelaxation (VR) occurs despite RG14202 being 275-fold selective for the rat brain A1 receptor. VR in response to RG14202 was attenuated markedly by the nonselective adenosine antagonist CGS15943, whereas 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), a highly selective A1 antagonist, had only a small inhibitory effect. In contrast, the potassium channel blocker glybenclamide attenuated RG14202-induced VR markedly (85-fold), indicating that modulation of potassium channels is likely involved. In carotid arterial rings, RG14202 was approximately 5 times less potent than in the coronary artery, suggesting that this compound may be more selective for the coronary vasculature. In anesthetized rats, i.v. administration of RG14202 caused a significant decrease in mean arterial pressure only at the highest dose (3 micrograms/kg). In comparison, heart rate was decreased dose- dependently with maximal changes at 3 micrograms/kg. Both the depressor and bradycardic responses could be antagonized with CGS15943. RG14202 increased renal, but had no effect on mesenteric or hindquarter vascular resistance. Glybenclamide pretreatment (20 mg/kg) did not significantly alter the effects of RG14202 on heart rate or regional vascular resistances; however, the depressor response to RG14202 was attenuated.(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
|
|
 |
|
  H. E. Tawfik, B. Teng, R. R. Morrison, J. Schnermann, and S. J. Mustafa Role of A1 adenosine receptor in the regulation of coronary flow Am J Physiol Heart Circ Physiol, July 1, 2006; 291(1): H467 - H472. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Bilder, T. Wentz, R. Leadley, D. Amin, L. Byan, B. O'Conner, S. Needle, H. Galczenski, J. Bostwick, C. Kasiewski, et al. Restenosis Following Angioplasty in the Swine Coronary Artery Is Inhibited By an Orally Active PDGF-Receptor Tyrosine Kinase Inhibitor, RPR101511A Circulation, June 29, 1999; 99(25): 3292 - 3299. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Van Schaick, R. A. A. Mathôt, J. M. Gubbens-Stibbe, M. W. E. Langemeijer, H. C. P. F. Roelen, A. P. Ijzerman, and M. Danhof 8-Alkylamino-Substituted Analogs of N6-Cyclopentyladenosine Are Partial Agonists for the Cardiovascular Adenosine A1 Receptors in Vivo J. Pharmacol. Exp. Ther., November 1, 1997; 283(2): 800 - 808. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
